Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain
NCT ID: NCT00366431
Last Updated: 2019-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
420 participants
INTERVENTIONAL
2006-08-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
NCT00804141
Double-Blind, Double-Dummy, 2-Period Crossover of a 20-Minute Versus a 4-hour IV of MOA-728 in Stable Methadone Subjects
NCT00444158
A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation
NCT01040637
Study Evaluating IV Methylnaltrexone for the Treatment of Post Operative Ileus
NCT00387309
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
NCT01367574
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MOA-728
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Taking oral, transdermal, intravenous, or subcutaneous opioids.
* Willingness to discontinue all pre-study laxative therapy and utilize only study permitted rescue laxatives.
Exclusion Criteria
* Other GI disorders known to affect bowel transit.
* Women who are pregnant, breast-feeding, or plan to become pregnant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bausch Health Americas, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Salix Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jeff Cohn
Role: STUDY_DIRECTOR
Bausch Health Americas, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Mobile, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Tucson, Arizona, United States
Hot Springs, Arkansas, United States
Anaheim, California, United States
Anaheim, California, United States
Bakersfield, California, United States
Foothill Ranch, California, United States
Garden Grove, California, United States
Los Gatos, California, United States
Orange, California, United States
Sacramento, California, United States
San Diego, California, United States
San Diego, California, United States
San Diego, California, United States
Trumbull, Connecticut, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Jupiter, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
Miami, Florida, United States
Ocala, Florida, United States
Ormond Beach, Florida, United States
Saint Cloud, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Dawsonville, Georgia, United States
Marietta, Georgia, United States
Marietta, Georgia, United States
Bloomington, Illinois, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Elkridge, Maryland, United States
Boston, Massachusetts, United States
Brockton, Massachusetts, United States
Saginaw, Michigan, United States
Traverse City, Michigan, United States
Picayune, Mississippi, United States
Independence, Missouri, United States
Missoula, Montana, United States
Omaha, Nebraska, United States
Reno, Nevada, United States
Haddon Heights, New Jersey, United States
Albuquerque, New Mexico, United States
Great Neck, New York, United States
Lake Success, New York, United States
Charlotte, North Carolina, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Clinton, Oklahoma, United States
Chattanooga, Tennessee, United States
Beaumont, Texas, United States
Colleyville, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
San Antonio, Texas, United States
Alexandria, Virginia, United States
Christiansburg, Virginia, United States
Norfolk, Virginia, United States
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3200A3-200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.